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To determine if there are significant 
differences in biochemical characteristics, 
biopsy variables, histopathological data, and 
rates of prostate-specific antigen (PSA) 
recurrence between African-American (AA) 
and white American (WA) men undergoing 
radical prostatectomy (RP), as AA men are 
twice as likely to die from prostate cancer 




We established a cohort of 1058 patients (402 
AA, 646 WA) who had RP and were followed 
for PSA recurrence. Age, race, serum PSA, 
biopsy Gleason score, clinical stage, 
pathological stage, and PSA recurrence data 
were available for the cohort. The chi-square 




-tests were used to 
assess basic associations with race, and log-
rank tests and Cox regression models for time 
to PSA recurrence. Forward stepwise variable 
selection was used to assess the effect on the 
risk of PSA recurrence for race, adjusted by 




The AA men had higher baseline PSA levels, 
more high-grade prostatic intraepithelial 
neoplasia (HGPIN) in the biopsy, and more 
HGPIN in the pathology specimen than WA 





PSA doubling time before RP, at 4.2 (4.7) vs 
5.2 (5.9) years. However, race was not an 
independent predictor of PSA recurrence 
 
In a multi-institutional study
authors from the USA and Austria
attempt to determine if there are
differences in several indices
between African-American and
white men undergoing radical
prostatectomy. They did not find
race to be an independent risk
factor for PSA recurrence, but
found that other variables
commonly associated with PSA
recurrence are also important in
African-Americans.
Using data extracted from the
Hospital Episodes database,
authors from England describe
national trends in radical
nephrectomy between 1995 and
2002. They found a considerable
increase in the annual number of
radical nephrectomies, with an
expected increase in the number of
laparoscopic procedures. They also
found a decrease in emergency
admissions and length of hospital
stay.
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This study indicates that while there are racial 
differences in baseline serum PSA and 
incidence of HGPIN, race is not an 
independent risk factor for PSA recurrence. 
Rather, other variables such as pathology 
Gleason score, bilateral cancers, HGPIN and 
margin positivity are independently 
associated with PSA recurrence. The PSA 
doubling time after recurrence may also be 
important, leading to the increased mortality 




prostate cancer, African-American, PSA 
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The number of new cases of prostate cancer 
was estimated at 513 000 worldwide and 
173 000 in the USA, accounting for 15.3% of 
all cancers in men in developed countries in 
2000 [1]. Within the next 15 years, prostate 
cancer is predicted to be the most common 
cancer in men [1]. The incidence of prostate 
cancer varies widely among ethnic 
populations, and the rate of this disease can 
differ by as much as 90 times among various 
populations. Specifically, African-American 
(AA) men in the USA have the highest 
incidence of prostate cancer (137 per 
100 000 per year) [2].
According to the 2000 USA Census, AAs 
comprise the second largest racial group in 
the USA; that AA men have a 2.5 times greater 
mortality from prostate cancer than white 
Americans (WA) has become a significant 
health concern in the USA [2]. This strikingly 
higher mortality for AA men raises several 
questions. Is the difference in mortality a 
result of diagnosis at later, more advanced 
disease stages? Or is it because prostate 
cancer is more biologically aggressive in AA 
men? [3]. It may also be possible that AA men 
are receiving different treatments for their 
prostate cancer than other populations [4]. In 
addition, is there a role for competing causes 
of death such as comorbidity and age? Finally, 
do poverty, socio-economic status and 
education have a role? [4].
Several authors [4–10] have examined an 
important surrogate, PSA recurrence, as a 
measure of prostate cancer-specific mortality. 
These studies evaluated clinical and 
pathological variables before and after 
surgery, socio-economic factors, and delivery 
of healthcare; the results are conflicting 
[4–10]. Recently there has been interest in the 
PSA doubling time as a surrogate for the 
ultimate outcome of prostate cancer [11]. 
Differences in PSA doubling times before and 
after treatment among races have been 
studied in a few series [5], but there is no 
comprehensive report of this subject in AAs in 
an equal-access setting. To address this issue, 
we evaluated differences in PSA doubling 
times, histopathological variables, and the 
incidence of PSA recurrence between AA and 
WA men with clinically localized prostate 
cancer. Accordingly, the analysis was limited 
to patients undergoing radical retropubic 
prostatectomy (RP) to ensure the availability 





This retrospective cohort study was aimed at 
comparing pathological stage and PSA 
recurrence in AA and WA men with prostate 
cancer and who were treated with RP at a 
large healthcare system in the mid-West USA, 
the Henry Ford Health System (HFHS), a 
vertically integrated healthcare system 
incorporating the nation’s 10th largest health 
maintenance organization. The population 





30% of the patients being AA. The 
HFHS has a computerized medical 
information system and medical record 
database. Comprehensive data are also 
available from computerized health-claims 
databases. This study was part of an 
Institutional Review Board-approved project 
for evaluating the effect of various 
demographic, clinical and histopathological 
variables on prostate cancer recurrence.
HFHS maintains a computerized tumour 
registry database accredited by the American 
College of Surgeons. Registry staff use a 
thorough case-finding system, including a 
review of all pathology and cytology reports, 
and radiation and oncology consultations. The 
American Joint Commission on Cancer system 
is used to determine the stage of disease by 
evaluating tumour size, extent of invasion, 
microscopic involvement of lymph nodes and 
presence of metastases. HFHS Registry 
staff link this data with the Detroit area 
Surveillance, Epidemiology and End Results 
Program records, and conduct an annual 
follow-up for vital status and recurrence; the 
annual follow-up is estimated at 94%. Thus 
the tumour registry of the HFHS was searched 
for all patients with an ICD-9 code of 185 
(prostate cancer), who were treated by RP and 
followed during the period 1 January 1990 to 
31 December 2000; only men with localized 
cancer (i.e. a negative bone scan) were 
included in the study.
Patients were excluded who were not AA or 
Caucasian, as were those who had incomplete 
follow-up information. Patients who 
developed bone metastasis within a year of 
diagnosis were also excluded, as we felt that 
these men most likely had pre-existing 
metastatic disease. Patients were also 
excluded if they received preoperative 
hormonal, radiation, cryotherapy, or received 
immediate adjuvant hormonal or radiation 
therapy for extracapsular disease, including 
seminal vesicle involvement.
The diagnosis of cancer was established by 
histological examination of prostate biopsy 
specimens by HFHS pathologists; tumour 
grade was reported as Gleason score 2–10, 
and the disease was staged using the 1992 
TNM classification.
Relevant baseline variables were recorded, e.g. 
race, age, clinical stage, serum PSA, biopsy 
Gleason score (minor and major), side(s) of 
positive cores, perineural infiltration (PNI), 
high-grade prostatic intraepithelial neoplasia 




Recurrence-free survival estimates by race 
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Pathological variables after RP were also 
recorded, e.g. specimen weight, pathological 
stage, PNI, HGPIN, prostatic inflammation, 
percentage tumour, margin status, seminal 
vesicle involvement, and lymph node spread. 
The baseline (preoperative) PSA doubling time 
was calculated by a linear regression model 
using at least four PSA values.
The primary endpoint of the analysis was the 
difference in PSA recurrence and doubling 
time. PSA recurrence was defined as two or 




0.2 ng/mL. The PSA doubling time after 
recurrence required at least three PSA values 
during the follow-up [11]. The secondary 
endpoints were differences in pathological 
variables, e.g. percentage cancer, HGPIN, PNI, 
inflammation, margin status, seminal vesicle 
invasion and lymph node spread.
A univariate analysis was used to compare the 
pathological variables at baseline and after RP 
between the racial groups. Comparisons of 
PSA recurrence were based on survival 
analysis. The Cox proportional-hazards model 
was used for multivariate survival analysis, 
which allowed an estimate of the PSA 
recurrence time, controlling for differences in 
follow-up time and risk factors that may 
affect survival, including confounding 
variables and effect modifiers. All relative risks 
were derived from the multivariate Cox 
models. Adjusted survival curves were 
generated using the empirical cumulative 
hazard estimate of the survivor function. 
Differences in the duration of survival were 
calculated by measuring differences in the 









The baseline characteristics of the cohort of 
1058 patients are summarized in Table 1. An 
important and surprising finding of the study 
was that at baseline, AA men had a shorter 
PSA doubling time than WA men (Table 1).
Table 1 also summarizes the study endpoints 
between the cohorts; even though PSA 
recurrence was no different between the 
racial groups, after PSA recurrence was 
diagnosed the PSA level increased at a faster 
rate in AA men than WA men. This was not 
statistically significant because the doubling 
time was calculable only in a few patients 




Baseline and histopathological characteristics between AA and WA
 










age, years 63.0 (6.5) 62.8 (6.9) 0.499





PSA doubling time, years 5.2 (5.9) 4.2 (4.7) 0.015






T1b 5 (1) 3 (1)
T1c 383 (70) 285 (78)
T2a 128 (23) 54 (15)
T2b 34 (6) 22 (6)















Primary Gleason grade 3.0 (0.6) 3.1 (0.6) 0.105
Gleason score 6.2 (1.1) 6.3 (1.1) 0.168
Percentage cancer, n (%):
PNI 35 (6) 27 (7) 0.389
HGPIN 53 (8) 50 (13) 0.025






Biopsy % cancer 13.8 (14.5) 15.0 (14.5) 0.278
Positive cores
unilateral 370 (59) 246 (62%) 0.290
bilateral 256 (41) 148 (38)
 
Pathological variables, n (%)
 
Stage 0.050
T2a 85 (13) 47 (12)
T2b 370 (57) 228 (58)
T2c 18 (3) 19 (5)
T3a 114 (17) 49 (12)
T3b 57 (9) 49 (12)






Specimen weight, g 47.4 (19.8) 51.1 (23.4) 0.010
Primary Gleason grade 3.2 (0.9) 3.2 (0.6) 0.291
Gleason score 6.6 (1.1) 6.7 (1.2) 0.272
Percentage cancer 19.9 (15.7) 21.3 (16.4) 0.128
N (%):
PNI 110 (17) 73 (18) 0.549
HGPIN 113 (17) 94 (24) 0.013
Inflammation 18 (3) 11 (3) 0.999
Margin positive status 181 (28) 119 (30) 0.475
Seminal vesicle invasion 57 (9) 49 (12) 0.065
Lymph node spread 21 (3) 12 (3) 0.851






PSA doubling time, years* 9.7 (13.5) 5.9 (8.1) 0.071
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difference in PSA doubling time between the 
racial groups. None of the other study 
endpoints, i.e. margin positivity, seminal 
vesicle infiltration and lymph node spread, 
were statistically different between the 
cohorts.
As shown in Table 2, AA origin was not an 
independent predictor of PSA recurrence in 
the univariate model. Other known variables, 
e.g. clinical stage, Gleason score, percentage 
cancer and pathological stage, were 
significantly associated with PSA recurrence. 
Importantly, HGPIN and specimen weights 
were also important predictors of recurrence. 
HGPIN had a hazard ratio (HR) of 1.8, and 
greater than margin positivity (1.76) and 
Gleason score (1.46; Table 2).
In the Cox proportional-hazard model race 
was not an independent predictor of PSA 
recurrence (Table 2, HR 1.21), but other 
variables, e.g. biopsy HGPIN, unilateral cancers 
in the biopsy, pathology Gleason score and 
positive margin status, were independent 
predictors of PSA recurrence. Interestingly 
there was a counterintuitive significant 
association between clinical stages T1 and T2 
cancers, showing that T2 cancers had a lower 
HR for recurrence; we do not know the 




Overall mortality from prostate cancer is 
greater in AA than WA men; historically, this 
has been attributed to a more advanced 
tumour stage in AA men at diagnosis. More 
recently, increased awareness and the 
widespread use of PSA screening has 
dramatically increased the detection of earlier 
stage cancers. This has been associated with a 
clear improvement in mortality and survival 
rates, especially in AA men, where there has 
been an improvement of 21% in organ-
confined disease. Some have argued that the 
treatment outcome has been better in WA 
than AA men for localized prostate cancer, but 
others have argued that there is no significant 
racial difference in treatment outcome 
[4–7,9,10,12].
The present study indicates that there are 
racial differences in baseline serum PSA, PSA 
doubling times, clinical and pathological 
stages, and the incidence of HGPIN. However, 
race alone did not appear to be an 
independent risk factor for PSA recurrence. 
Rather, other variables, e.g. pathology Gleason 
score, bilateral cancers, HGPIN and margin 
positivity, were independently associated with 
PSA recurrence. The present study is unique in 
that it includes a significant proportion of AA 
patients (38%) and has many additional 
variables that could affect PSA recurrence. 
Further, we also showed that while PSA 
recurrence rates are no different between AA 
and WA men, PSA levels double much faster in 
the former than the latter. The biological 
significance of a rapid PSA doubling time is 
currently unknown, but given the association 
of a rapid PSA doubling with earlier 
development of metastasis [11,13], it can be 
postulated that after PSA recurrence, AA men 
may have a more aggressive course of disease. 
This finding is in contrast with results from a 




 [5], who 
reported that the mean average relative PSA 
velocity for AA and WA men having disease 









 0.21). The rate of PSA 
increase in patients who developed disease 
recurrence after RP was 18.9% per month for 









 0.73). The present results may differ 
because the follow-up was longer 





, where the median follow-up was 
39 months. The brevity of the PSA doubling 
time was also noted before RP in the present 
series, but the significance of this finding is 
unknown. Several studies reported that a 
rapid PSA doubling time may be associated 
with more aggressive disease [4–7,9,10,12]. 
We postulate that even though PSA 
recurrence rates are comparable, AA men who 
develop PSA recurrence may have a more 
accelerated course of disease. This hypothesis 
is currently being tested at our centre in 
patients for whom long-term survival data 
are available.
Whether race is truly predictive of PSA 
recurrence after RP has been controversial. 
Earlier reports stated that race is an 
independent predictor of outcome, while 













AA 1.18 (0.93–1.48) 0.169 1.21 (0.89–1.64) 0.225
Age, decades 0.86 (0.72–1.03) 0.093 0.74 (0.58–0.95) 0.017
PSA 1.00 (0.99–1.00) 0.613 0.99 (0.98–1.01) 0.377
Log PSA 1.01 (0.90–1.12) 0.924 –









0.001 1.11 (0.93–1.32) 0.254
Biopsy inflammation 1.15 (0.43–3.08) 0.788 0.66 (0.20–2.16) 0.493
Biopsy PNI 1.17 (0.78–1.77) 0.449 1.47 (0.87–2.48) 0.146
Biopsy HGPIN 1.80 (1.22–2.64) 0.003 1.81 (1.13–2.91) 0.014

















0.001 0.99 (0.98–1.00) 0.059




0.001 1.00 (0.99–1.02) 0.443


















N stage 1.39 (0.86–2.25) 0.174 1.35 (0.70–2.59) 0.366
Seminal vesicles 1.58 (1.18–2.12) 0.002 0.97 (0.60–1.57) 0.910













0.001 0.89 (0.60–1.31) 0.548
PNI 1.08 (0.81–1.43) 0.611 1.39 (0.90–2.14) 0.138
HGPIN 0.80 (0.59–1.09) 0.162 0.84 (0.52–1.36) 0.472
Inflammation 0.65 (0.24–1.76) 0.401 0.79 (0.19–3.40) 0.756
 








no racial disparity in progression-free survival 
among men with clinically localized prostate 










65 years) were evaluated, and 
they had a greater risk of recurrence. Using 
multivariate modelling, we re-examined this 
issue in the present cohort, but there was no 
statistically significant racial difference in 
younger AA patients. This discrepancy could 
be attributed to an inherent difference in the 









 1% clinical 
stage T3 cancer.
The present findings are robust because the 
analysis involved patients from an equal-
access system, which minimizes potential 
access-related issues in healthcare. Other 
studies [9] showed that lack of healthcare 
insurance and barriers to access could delay 
diagnosis and affect outcome. Therefore, the 
present study is more suitable for determining 
whether race is an independent factor for PSA 
recurrence; we conclude that race is not 
independently associated with PSA recurrence 
but must acknowledge that AA men have a 
shorter PSA doubling time, which may 
translate into more aggressive disease. Our 
centre is currently studying long-term data 
from these patients.
Another strength of the present study 
is that it includes several additional 
histopathological variables which could affect 
PSA recurrence. Specifically, we assessed 
differences in PNI, inflammation and 
percentage cancer in the biopsy. None of 
these variables was more prevalent in AA 
patients, but the incidence of HGPIN was 
significantly greater in AA men and associated 
with a greater incidence of PSA recurrence. An 
important limitation of the study is its 
retrospective design, but the large sample size 
and inclusion of several confounding 
variables potentially offset this limitation.
In conclusion, AA race is not an independent 
risk factor for PSA recurrence in patients 
undergoing RP, and AA men have no greater 
incidence of HGPIN, higher baseline PSA level, 
or rapid PSA doubling before RP or after 
recurrence. Early PSA testing and aggressive 
evaluation of abnormal PSA, and of HGPIN, 
could result in the diagnosis of early prostate 
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Prostate cancer in the African 
















 Race, treatment, and long-term 
survival from prostate cancer in an equal-
















Prostate specific antigen progression 
after radical prostatectomy in African-

















Race is not an independent predictor of 
biochemical recurrence after radical 

















Is ethnicity an independent predictor of 
















 Predicting recurrence after radical 
















 Black race is an adverse prognostic 
factor for prostate cancer recurrence 
following radical prostatectomy in an 

















Prostate cancer biochemical recurrence 
stage for stage is more frequent among 
African-American than white men with 
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Prostate-specific antigen as a marker of 
















Outcome of African American men 
screened for prostate cancer: the Detroit 



























Keynote address: prostate 
cancer among African-American men – 

















Should African-American men be tested 
for prostate carcinoma at an earlier age 
















free survival difference between African 
Americans and whites after radical 
prostatectomy for local prostate cancer: a 
multivariable analysis. 
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